Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly reports ‘safety and efficacy’ of Zyprexa

Eli Lilly reports ‘safety and efficacy’ of Zyprexa

11th February 2008

Eli Lilly has reported that Zyprexa (olanzapine LAI) has been shown to be a safe and effective treatment and maintenance treatment for adults with schizophrenia.

Zyprexa LAI is an investigational formulation combining a pamoate salt with the atypical antipschotic drug Zyprexa for extended delivery of up to one month.

The long-acting injection has been adjudged to be a suitable therapy for the condition by the psychopharmacologic drugs advisory committee of the US Food and Drug Administration (FDA), as long as it is appropriately labelled around excessive sedation events.

John Hayes, vice-president of Lilly Research Laboratories, said: “Due to the chronic and severe nature of the illness and the limited number of approved long-acting formulations, we believe that, if approved, Zyprexa LAI could be an important treatment option for this patient population.”

He added that this group of patients often struggle with their medication, while the company is happy with the recommendation of the FDA committee and will continue to work with the association on its application.

In June 2007, Eli Lilly responded to court rulings in Germany and Canada regarding the patents for Zyprexa which could facilitate the entry of generic forms of the drugs into those countries as deeply flawed.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.